Ganirelix Powder Cas No.123246-29-7

We specialise in the production of high-purity Ganirelix acetate active pharmaceutical ingredient (API), manufactured in strict compliance with pharmaceutical-grade quality standards. The entire production process is conducted under cGMP guidance, ensuring exceptional product homogeneity and batch-to-batch consistency. Our Ganirelix acetate exhibits outstanding chemical and biological stability, making it ideal for formulation development.

As a trusted API partner, we are committed to providing clients with high-quality, regulatory-compliant products to support your robust development within the global assisted reproductive technology sector. We welcome your enquiries and look forward to potential collaboration.

Ganirelix Acetate is a highly effective Gonadotropin-Releasing Hormone (GnRH) antagonist. Its primary pharmacological action is to rapidly and reversibly suppress pituitary secretion of Luteinizing Hormone (LH), thereby effectively preventing a premature LH surge during fertility treatment cycles. This precise inhibitory effect is crucial for maintaining the normal developmental trajectory of ovarian follicles.

As a synthetic decapeptide, Ganirelix Acetate works by competitively blocking GnRH receptors on the pituitary gonadotroph cells. It binds to these receptors with high affinity, directly occupying the receptor sites and preventing endogenous GnRH from binding. Since it does not initiate an initial "flare-up" effect, it immediately suppresses immediately suppresses the secretion of both LH and Follicle-Stimulating Hormone (FSH), enabling rapid hormonal control.

The core efficacy of this product in clinical application is the prevention of premature ovulation during controlled ovarian stimulation. Through timely administration, it ensures a greater number of follicles can mature, thereby increasing the oocyte retrieval rate and the number of high-quality embryos available for transfer. Its use in Assisted Reproductive Technology helps optimize treatment protocols and improve overall success rates.

This product serves as an Active Pharmaceutical Active Pharmaceutical Ingredient (API) specifically used in the formulation of injectable preparations for Assisted Reproductive Technology. It is primarily indicated for infertile patients undergoing controlled ovarian stimulation, administered during the mid-to-late phase of the stimulation protocol to effectively curb a premature LH surge and ensure the successful progression of the egg retrieval procedure. Its highly specific action makes it a key agent in modern short-protocol ovulation induction cycles.

Hot Tags: ganirelix powder cas no.123246-29-7, China ganirelix powder cas no.123246-29-7 manufacturers, suppliers, factory, tranexamic powder